While CD226 blockade alone did not alter tumor growth or mortality in various mouse tumor models, including CT26, RENCA or lung metastasis models69–71, co-treatment of anti-CD226 mAb with anti-TIGIT and anti-PD-L1 mAbs or anti-PD-1 and anti-GITR mAbs inhibited antitumor responses mediated by the combined treatment with those mAbs. The gene discussed is TIGIT; the disease is neoplasm.